

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6125831

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BELLUS HEALTH (INTERNATIONAL) LIMITED	03/29/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BELLUS HEALTH INC.
<b>Street Address:</b>	275 ARMAND-FRAPPIER BOULEVARD
<b>Internal Address:</b>	LAVAL
<b>City:</b>	QUEBEC
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	H7V 4A7
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16857520
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617 477-2473
<b>Email:</b>	lromano@cooley.com
<b>Correspondent Name:</b>	THOMAS J. PAXTON
<b>Address Line 1:</b>	COOLEY LLP
<b>Address Line 2:</b>	1299 PENNSYLVANIA AVENUE NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	ALZH-001/06US
<b>NAME OF SUBMITTER:</b>	THOMAS J. PAXTON
<b>SIGNATURE:</b>	/Thomas J. Paxton/
<b>DATE SIGNED:</b>	05/28/2020
<b>Total Attachments: 3</b>	
source=ALZH-00106US -Assignment Bellus Health Int Ltd to Bellus Health Inc#page1.tif	
source=ALZH-00106US -Assignment Bellus Health Int Ltd to Bellus Health Inc#page2.tif	
source=ALZH-00106US -Assignment Bellus Health Int Ltd to Bellus Health Inc#page3.tif	

## ASSIGNMENT

BELLUS HEALTH (INTERNATIONAL) LIMITED, in liquidation, a Corporation organized under the laws of Switzerland, having its principal place of business at PSE-Parc Scientifique sur le site de l'Ecole Polytechnique Fédérale de Lausanne à Ecublens, CH-1015 Lausanne, Switzerland, (the "Assignor") in consideration of valuable consideration paid to it by

BELLUS HEALTH INC.

a Corporation organized under the Canada Business Corporations Act, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, the receipt of which is hereby acknowledged, does hereby sell, assign and transfer unto said


BELLUS HEALTH INC.

its successors and assigns (collectively the "Assignee"), the entire interest for Canada, the United States of America, and all foreign countries in certain invention(s) or improvement(s) described in the Patents and Applications listed in Schedule A, including all rights of priority under the International Convention for the Protection of Industrial Property, in any Patent Office, and in all Letters Patent of any country which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, reexamination, reissue, national phase, regional phase, validation, or other applications or patents based in whole or in part thereon, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted or extended, as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made. And the Assignor agrees, for itself and its successors and assigns, with the Assignee and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to the Assignee, with specifications and claims in such form as shall be approved by the counsel of said Assignee and to vest and confirm in the Assignee the legal title to all such patents.

And the Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of the United States and all other Patents Offices to issue such Letters Patent as shall be granted upon said application or applications based thereon to the Assignee.

On behalf of BELLUS HEALTH (INTERNATIONAL) LIMITED, in liquidation:


Date: March 29, 2011

  
\_\_\_\_\_

Name: Jeannine Huck  
Title: Liquidator

Witness:


Date: March 29, 2011

  
\_\_\_\_\_

Name: Ralph Schmid

On behalf of BELLUS HEALTH INC.:

Date: March 29, 2011

  
\_\_\_\_\_

Name: François Desjardins  
Title: Vice-president, Finance

Witness:

Date: March 29, 2011

  
\_\_\_\_\_

Name: NANCY BARRIAULT


Date: March 29, 2011

  
\_\_\_\_\_

Name: Roberto Bellini  
Title: President and Chief Executive Officer

Witness:

Date: March 29, 2011

  
\_\_\_\_\_

Name: NANCY BARRIAULT

SCHEDULE A

050: Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

<u>Country</u>	<u>Patent/Application No.</u>
U.S.A.	60/851,039
U.S.A.	60/911,459
U.S.A.	11/871,639
PCT	PCT/IB2007/004704
Australia	2007357451
Brazil	PI 0717794-1
Canada	2,666,246
China	200780037964.1
Eurasia	200970287
Europe	07875176.5
Hong Kong	10101380.4
Israel	197852
India	3005/DELNP/2009
Japan	2009-531940
Republic of Korea	10-2009-7008847
Mexico	MX/a/2009/003768
New Zealand	576285
Singapore	200902406-8
South Africa	2009/03030